Hematologic Malignancy
Mature B-Cell Non-Hodgkin Lymphoma
CI-CAN-00003259Explore in graph →
Hematologic792 active trials17 approved drugs43 evidence items
- NCIt
- C7056
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003259Explore in graph →
Clinical trials
2,506 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (393)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01859819 | Treatment for Advanced B-Cell Lymphoma(REBOOT) | completed | Phase 2 | 45 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT02013128 | Ublituximab + Ibrutinib in Select B-cell Malignancies | completed | Phase 1 / Phase 2 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT00114738 | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2022 | clinicaltrials |
| NCT01775475 | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | completed | Phase 2 | 7 | AIDS Malignancy ConsortiumNETWORK | 2 | Oct 10, 2022 | clinicaltrials |
| NCT02756247 | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | completed | Phase 1 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT01030900 | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03425591 | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice(FIRE) | completed | — | 508 | Janssen-Cilag Ltd.INDUSTRY | 1 | Oct 6, 2022 | clinicaltrials |
| NCT01886859 | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05541328 | Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | completed | — | 169 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2022 | clinicaltrials |
| NCT03036904 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas(V+DA-EPOCH-R) | completed | Phase 1 | 31 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04150328 | Lenalidomide Monotherapy in R/R DLBCL(RE-MIND) | completed | — | 490 | MorphoSys AGINDUSTRY | 4 | Aug 24, 2022 | clinicaltrials |
| NCT00199082 | Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | completed | Phase 4 | 650 | Nicola GoekbugetOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT03527147 | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)(PRISM) | completed | Phase 1 | 30 | Acerta Pharma BVINDUSTRY | 2 | Aug 15, 2022 | clinicaltrials |
| NCT03630159 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients(PORTIA) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 3 | Aug 15, 2022 | clinicaltrials |
| NCT01662050 | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL(FIL-RBAC500) | completed | Phase 2 | 57 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT01514344 | Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma(IRIS) | completed | Phase 2 | 20 | Andres J. M. FerreriOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01516593 | Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma(CARMEN) | completed | Phase 2 | 19 | Andres J. M. FerreriOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03297424 | A Study of PLX2853 in Advanced Malignancies. | completed | Phase 1 | 49 | Opna Bio LLCINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05366257 | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) | completed | — | 160,602 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05349201 | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | completed | — | 273 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02049541 | Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 1 | 18 | Kami Maddocks, MDOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02063685 | Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma | completed | Phase 3 | 807 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02710643 | "MIRO" Molecularly Oriented Immuno-radio-therapy(FIL_MIRO) | completed | Phase 2 | 110 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02877550 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | completed | Phase 1 | 25 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT02419560 | Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | completed | Phase 1 | 37 | Craig Portell, MDOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT03682796 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | completed | Phase 1 | 32 | Triphase Research and Development III Corp.INDUSTRY | 2 | May 19, 2022 | clinicaltrials |
| NCT02677324 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT02631577 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT02471911 | KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma(KPT-330+RICE) | completed | Phase 1 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01791595 | A Phase I Trial of AZD3965 in Patients With Advanced Cancer | completed | Phase 1 | 53 | Cancer Research UKOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | completed | Phase 1 / Phase 2 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03465527 | Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL | completed | Phase 2 | 37 | Kosin University Gospel HospitalOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03364439 | R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients(FIL_DLCL10) | completed | Phase 2 | 109 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04465162 | Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02736617 | Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01481272 | Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients(PLRG8) | completed | Phase 2 | 77 | Polish Lymphoma Research GroupNETWORK | 1 | Dec 27, 2021 | clinicaltrials |
| NCT05169203 | The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study(COO-CNS) | completed | — | 2,969 | Herlev HospitalOTHER | 0 | Dec 23, 2021 | clinicaltrials |
| NCT02639910 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi(COSMOS) | completed | Phase 2 | 24 | MorphoSys AGINDUSTRY | 6 | Dec 20, 2021 | clinicaltrials |
| NCT03104478 | Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)(RT3) | completed | — | 219 | The Lymphoma Academic Research OrganisationOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | completed | Phase 3 | 368 | Medical College of WisconsinOTHER | 1 | Dec 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2022source: clinicaltrials